Corpus ID: 23069595

Autophagy: novel action of panitumumab in colon cancer.

@article{Giannopoulou2009AutophagyNA,
  title={Autophagy: novel action of panitumumab in colon cancer.},
  author={Efstathia Giannopoulou and Anna Antonacopoulou and Panagiota Matsouka and Haralabos P Kalofonos},
  journal={Anticancer research},
  year={2009},
  volume={29 12},
  pages={
          5077-82
        }
}
BACKGROUND Panitumumab, a fully-human monoclonal antibody raised against epidermal growth factor receptor (EGFR), has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma (mCRC) after failure of standard chemotherapy. Additionally, the guideline of the EMEA includes the use of panitumumab in patients with wild-type KRAS. The goal of the current study was to… Expand
Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.
TLDR
A combination therapy comprising of anti-EGFR MoAbs and autophagy inhibitors would represent a multi-pronged approach that could be evolved into an active therapeutic strategy in mCRC patients. Expand
Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status
TLDR
The results suggest that response to Panitumumab treatment is not only controlled by the KRAS status but may also be essentially influenced by other regulating factors. Expand
The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines
TLDR
The benefit from a dual targeting of aromatase and EGFR seems to be regulated by NSCLC cell content, and the diverse responses of cells to agents might be influenced by the dominance of certain molecular pathways. Expand
The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III
TLDR
EGFRvIII could induce autophagy, and CH12 treatment could improve autophagic activity in EGFRv III-positive liver cancer cells, and the combination of CH12 with an autophophagy inhibitor or siRNA against key proteins in the autophile pathway displayed more significant efficacy on EGFR vIII-positive tumor cells than monotherapy, and induced cell apoptosis. Expand
Panitumumab: a review of its use in metastatic colorectal cancer.
TLDR
In patients with wild-type KRAS tumours, panitumumab is a useful option in combination with chemotherapy for the first- and second-line treatment of metastatic colorectal cancer or as monotherapy for the treatment of chemotherapy-refractory metastatic cancer. Expand
Panitumumab: a summary of clinical development in colorectal cancer and future directions.
TLDR
Ten years of drug development is reviewed, focusing on the clinical evidence for panitumumab's indication in metastatic colorectal cancer and future strategies of investigation, to identify patients with higher chances of benefiting from the treatment. Expand
Autophagic action of new targeting agents in head and neck oncology
TLDR
The possible role of autophagy as a novel target for anticancer therapy agents in HNSCC is discussed, including cetuximab, which has shown promising results in combination with radiation. Expand
Spotlight on Panitumumab in Metastatic Colorectal Cancer
TLDR
In patients with wild-type KRAS tumors, panitumumab is a useful option in combination with chemotherapy for the first- and second-line treatment of metastatic colorectal cancer or as monotherapy for the treatment of chemotherapy-refractory metastatic cancer. Expand
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
Introduction: Integration of targeted therapy and additional chemotherapy options has improved median overall survival (OS) in patients with unresectable metastatic colorectal cancer (mCRC).Expand
Panitumumab: leading to better overall survival in metastatic colorectal cancer?
TLDR
A review of biomarker research with expanded Ras testing has led to an improvement in overall survival for all Ras wild-type patients treated with panitumumab, and the thorough evaluation of markers within the EGFR pathway could potentially prevent detrimental effects for patients treated for metastatic colorectal cancer and avoid unnecessary toxicity and costs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Dual targeting of EGFR and HER-2 in colon cancer cell lines
TLDR
The inhibitory effect of these agents on cell proliferation and the induction of apoptosis differ for the two colon cancer cell lines under consideration, and further studies are necessary to investigate the way they exert their antitumor effect. Expand
Epidermal growth factor receptor as a target for chemotherapy.
TLDR
Clinical phase III trials in patients with non-small-lung cancer suggest that sequential rather than concurrent erlotinib/gefitinib-based treatment provides a benefit in clinical outcome, suggesting that EGFR-targeting agents are reasonably well tolerated and have limited overlapping toxicities in combination with other cytotoxic drugs. Expand
Pharmacology of epidermal growth factor inhibitors.
TLDR
New combinatorial approaches are being explored with the aim of improving the potency and pharmacokinetics of EGFR inhibition, to increase the synergistic activity in combination with chemotherapy and overcome resistance to the EGFR inhibitors. Expand
Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
TLDR
Panitumumab appears to have relatively acceptable tolerability and is now available as an additional option for patients with mCRC refractory to multiple chemotherapeutic regimens. Expand
FDA drug approval summary: panitumumab (Vectibix).
TLDR
Panitumumab approval is based on the results of a single, open-label, randomized, multinational study that enrolled 463 patients with EGFR-expressing metastatic colorectal cancer. Expand
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
TLDR
Understanding the actions of these agents is essential to improving their efficacy in the treatment of cancers, as many of the clinical trials reported so far have shown at best limited gains. Expand
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy.
TLDR
Important issues remain to be addressed, including the development of appropriate predictive markers for response, such as improved tests for EGFR activity, correlation of rash with response and potential pharmacogenomic approaches; the sequencing and combination ofThese agents with chemotherapy and irradiation; and the possible role of these agents in the treatment of patients with earlier stage disease. Expand
Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
TLDR
Panitumumab is a fully human IgG2 monoclonal antibody that in a randomized phase III trial was shown to increase efficacy when added to best supportive care in patients with chemotherapy-refractory metastatic CRC, and is being investigated in the first-line and second-line settings in randomized clinical trials. Expand
Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization
TLDR
It is suggested that autophagy knockdown may be useful in a combination therapy setting to sensitize breast cancer cells, including tamoxifen-resistant breast cancer Cells, to tamoxIFen therapy. Expand
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
  • R. Amado, M. Wolf, +9 authors David Chang
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy. Expand
...
1
2
3
4
5
...